Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor

Research output: Contribution to journalArticlepeer-review

Abstract

The synthesis and the structure of N-isopropyl-N′-[2-(3′-methylphenylamino)-5-nitrobenzenesulfonyl] urea (14) was drawn from two thromboxane A2 receptor antagonists structurally related to torasemide. Compound 14 showed an IC50 value of 22 nM for the thromboxane A2 (TXA2) receptor of human washed platelets. Compound 14 prevented platelet aggregation induced by arachidonic acid (0.6 mM) and U-46619 (1 μM) with an IC50 value of 0.45 and 0.15 μM, respectively. Moreover, 14 relaxed the rat isolated aorta and guinea-pig trachea precontracted by U-46619, a TXA2 agonist. Its efficacy (IC50) was 20.4 and 5.47 nM, respectively. Finally, 14 (1 μM) completely inhibited TXA2 synthase of human platelets. The pKa value and the crystallographic data of 14 were determined and used to propose an interaction model between the TXA2 antagonists related to torasemide and their receptor.

Original languageEnglish
Pages (from-to)669-80
Number of pages12
JournalJournal of Pharmacy and Pharmacology
Volume53
Issue number5
DOIs
Publication statusPublished - 1 May 2001

Keywords

  • Animals
  • Aorta
  • Arachidonic Acid
  • Guinea Pigs
  • Male
  • Platelet Aggregation
  • Rats
  • Rats, Wistar
  • Receptors, Thromboxane
  • Sulfonylurea Compounds
  • Thromboxane-A Synthase
  • Trachea

Fingerprint Dive into the research topics of 'Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A<sub>2</sub> receptor antagonist and thromboxane synthase inhibitor'. Together they form a unique fingerprint.

Cite this